Novel inotropic/lusitropic biologics against decompensated chronic heart failure
- Förderkennzeichen
81X2500173
- Projektnummer
883
- Institution
- Universitätsklinikum Heidelberg
- Projektleiter
- Patrick Most
- Standort
- Heidelberg/Mannheim
- Kurzbeschreibung
-
The objectives of this proposal are the preclinical development of a cardiac-targeted peptide drug with inotropic and lusitropic effects for the short-term intravenous treatment of …
The objectives of this proposal are the preclinical development of a cardiac-targeted peptide drug with inotropic and lusitropic effects for the short-term intravenous treatment of decompensated chronic heart failure (CHF) and its clinical translation into a first-in-human clinical trial. The life-threatening complication of the clinical syndrome presents a significant unmet medical need given its high mortality and severe adverse effects of clinical drugs to reconstitute cardiac performance. The proposed therapeutic innovation seeks to exploit a novel regulatory principle to improve cardiac contraction and relaxation by the molecular factor S100A1 and utilizes cell-permeable peptide technology that is derived from the molecules C-terminal domain. The translational research project originates from comprehensive preclinical data showing the ability of S100A1ct peptide for a reversible short-term improvement and protection of cardiac performance in vivo and in vitro. In its funded first developmental module, the project seeks to define the therapeutically effective dose-range of S100A1ct in clinically relevant large animal disease models as well as demonstration of toxicological and immunological safety to conclude regulatory steps on ultimate GMP/GLP pre-clinical and clinical development.
- Projektart
- Translational Research Project
- Fördersumme
- € 475.370,35
- Beginn
- 01.01.2018
- Ende
- 31.12.2019